ライフサイエンスコーパス: heart-lung

1 pose of this study is to review the National Heart Lung and Blood Institute (NHBLI) guidelines on scr

2 g from National Institute of Health/National Heart Lung and Blood Institute career development grants

3 a limited-access database from the National Heart Lung and Blood Institute's Viral Activation Transf

4 National Institutes of Health, National Heart Lung and Blood Institute, and US Environmental Pro

5 ty Executive, Department of Health, National Heart Lung and Blood Institute, National Institute on Ag

6 US National Heart Lung and Blood Institute, US National Institute of

7 cutive, UK Department of Health, US National Heart Lung and Blood Institute, US National Institute on

8 National Institute on Aging, National Heart Lung and Blood Institute.

9 dation, Intramural NIH funding, and National Heart Lung and Blood Institute.

10 nstitutes of Health (NIH) including National Heart, Lung and Blood Institute (NHLBI), the National In

11 asthma treatment and monitoring per National Heart, Lung and Blood Institute asthma guidelines.

12 ing CCTA as highlighted at the 2019 National Heart, Lung and Blood Institute CCTA Summit.

13 National Heart, Lung and Blood Institute Division of Intramural R

14 xamined the exome data set from the National Heart, Lung and Blood Institute Exome Sequencing Project

15 The National Heart, Lung and Blood Institute of the National Institut

16 African American subjects from the National Heart, Lung and Blood Institute's Family Blood Pressure

17 National Heart, Lung and Blood Institute, National Institutes of

18 eader through the new update of the National Heart, Lung and Blood Institute/National Asthma Educatio

19 lobal Initiative for Asthma and the National Heart, Lung and Blood Institute/National Asthma Educatio

20 National Heart, Lung and Blood Institute; Johns Hopkins Institute

21 t is expressed in multiple tissues including heart, lung and brain.

22 tion of TASK modulators for the treatment of heart, lung and sleep disorders.

23 nically stressed dynamic tissues such as the heart, lungs and tendons.

24 ortedly causing major adverse effects on the heart, lungs and the brain.

25 l decellularization of complex organs (i.e., hearts, lungs and kidneys) can be performed.

26 ealed the role of miR-17 approximately 92 in heart, lung, and B-cell development and in Myc-induced B

27 With the growing burden of HIV-related heart, lung, and blood (HLB) disease, the National Heart

28 with making recommendations to the National Heart, Lung, and Blood Advisory Council about how the Na

29 The National Heart, Lung, and Blood Advisory Council chose 6 topics t

30 matrix mechanics, which we illustrate across heart, lung, and blood development.

31 orking Group, Advancing HIV/AIDS Research in Heart, Lung, and Blood Diseases, charged with identifyin

32 y matched control subjects from the National Heart, Lung, and Blood Grand Opportunity Exome Sequencin

33 National Heart, Lung, and Blood Institute (1R01HL108441-01A1) and

34 anslational Sciences (UL1TR002377), National Heart, Lung, and Blood Institute (5R35HL139854 and R01 H

35 ation (Geneva, Switzerland) and the National Heart, Lung, and Blood Institute (Bethesda, Maryland) ha

36 orate the 70(th) Anniversary of the National Heart, Lung, and Blood Institute (NHLBI) and celebrate i

37 in HCM has been highlighted by the National Heart, Lung, and Blood Institute (NHLBI) as a research p

38 iovascular R01 grants funded by the National Heart, Lung, and Blood Institute (NHLBI) between 1980 an

39 For these reasons, the National Heart, Lung, and Blood Institute (NHLBI) convened a work

40 through lung disease research, the National Heart, Lung, and Blood Institute (NHLBI) convened a work

41 The National Heart, Lung, and Blood Institute (NHLBI) convened a Work

42 The National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencin

43 s (TCGA), the 1000 Genomes Project, National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencin

44 n Genome Research Institute (NHGRI)/National Heart, Lung, and Blood Institute (NHLBI) grant U54HG0065

45 The National Heart, Lung, and Blood Institute (NHLBI) of the National

46 scribes programmes supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National

47 as coordinated and supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National

48 IGN, SETTING, AND PARTICIPANTS: The National Heart, Lung, and Blood Institute (NHLBI) Pooled Cohorts

49 lung, and blood (HLB) disease, the National Heart, Lung, and Blood Institute (NHLBI) recognizes it m

50 ole-genome sequencing data from the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for

51 US National Heart, Lung, and Blood Institute (NHLBI), and The Cowlin

52 e major strategic objectives of the National Heart, Lung, and Blood Institute (NHLBI), one of the 27

53 This paper describes ongoing National, Heart, Lung, and Blood Institute (NHLBI)-initiated child

54 ventions that were supported by the National Heart, Lung, and Blood Institute (NHLBI).

55 National Heart, Lung, and Blood Institute (US National Institutes

56 had evolved in the decade since the National Heart, Lung, and Blood Institute 2004 working group repo

57 mples from subjects enrolled in two National Heart, Lung, and Blood Institute Acute Respiratory Distr

58 f the National Institutes of Health/National Heart, Lung, and Blood Institute Acute Respiratory Distr

59 preplanned interim analysis by the National Heart, Lung, and Blood Institute after unanimous recomme

60 National Heart, Lung, and Blood Institute and European Union Seve

61 US National Heart, Lung, and Blood Institute and National Cancer Ins

62 National Heart, Lung, and Blood Institute and National Institute

63 in Children and Adolescents of the National Heart, Lung, and Blood Institute and the 2013 Guideline

64 The National Heart, Lung, and Blood Institute and the Adult Congenita

65 d at 2 workshops cosponsored by the National Heart, Lung, and Blood Institute and the American Societ

66 The US National Heart, Lung, and Blood Institute and the European Societ

67 Intramural Research Program of the National Heart, Lung, and Blood Institute and the National Cancer

68 National Heart, Lung, and Blood Institute and the National Center

69 National Heart, Lung, and Blood Institute and UnitedHealth Group.

70 In 2008, the National Heart, Lung, and Blood Institute announced its intent to

71 al nutrition at 44 hospitals in the National Heart, Lung, and Blood Institute ARDS Clinical Trials Ne

72 atory distress syndrome (ARDS), the National Heart, Lung, and Blood Institute ARDS Clinical Trials Ne

73 In 2013, the National Heart, Lung, and Blood Institute assembled a working gro

74 The National Heart, Lung, and Blood Institute AsthmaNet consortium ha

75 National Heart, Lung, and Blood Institute at the National Institu

76 European-American samples from the National Heart, Lung, and Blood Institute Candidate Gene Associat

77 The National Heart, Lung, and Blood Institute closed SWiTCH after int

78 nts in a conference convened by the National Heart, Lung, and Blood Institute concluded that a signif

79 how population studies supported by National Heart, Lung, and Blood Institute contracts might be stra

80 On October 1 and 2, 2015, the National Heart, Lung, and Blood Institute convened a group of ext

81 The National Heart, Lung, and Blood Institute convened a group of lea

82 The National, Heart, Lung, and Blood Institute convened a Think Tank m

83 The National Heart, Lung, and Blood Institute convened a working grou

84 ress this challenging syndrome, the National Heart, Lung, and Blood Institute convened a working grou

85 In September 2017, the National Heart, Lung, and Blood Institute convened a Working Grou

86 In December 2011, the National Heart, Lung, and Blood Institute convened a workshop to

87 In 2008, the National Heart, Lung, and Blood Institute convened an Implementat

88 In 2008, the National Heart, Lung, and Blood Institute convened the Adult Trea

89 lood Advisory Council about how the National Heart, Lung, and Blood Institute could take advantage of

90 rding to American Heart Association/National Heart, Lung, and Blood Institute criteria and included a

91 ometrics to describe the use of the National Heart, Lung, and Blood Institute data repository.

92 Using the National Heart, Lung, and Blood Institute Dynamic Registry, we ev

93 trols; LifePool, 2010 controls; and National Heart, Lung, and Blood Institute Exome Sequencing Projec

94 4,313 European Americans) from the National Heart, Lung, and Blood Institute Exome Sequencing Projec

95 icipants randomly selected from the National Heart, Lung, and Blood Institute Exome Sequencing Projec

96 through simulation studies and the National Heart, Lung, and Blood Institute Exome Sequencing Projec

97 In the National Heart, Lung, and Blood Institute Exome Sequencing Projec

98 injury exome-sequencing data of the National Heart, Lung, and Blood Institute Exome Sequencing Projec

99 d CAC in 2703 participants from the National Heart, Lung, and Blood Institute Family Heart Study who

100 also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for

101 The National Heart, Lung, and Blood Institute funded 3 centers and a

102 789 Marfan patients enrolled in the National Heart, Lung, and Blood Institute GenTAC (Genetically Tri

103 encies in OC were compared with the National Heart, Lung, and Blood Institute GO Exome Sequencing Pro

104 , and (3) new coronary dissections >National Heart, Lung, and Blood Institute grade 3.

105 17 by the Boettcher Foundation, and National Heart, Lung, and Blood Institute grants R01HL14644 and R

106 National Heart, Lung, and Blood Institute guideline-adherent (mac

107 lled asthma, as defined by the 2007 National Heart, Lung, and Blood Institute guidelines' impairment

108 3 or step 4 combination therapy per National Heart, Lung, and Blood Institute guidelines, received IC

109 y poorly controlled asthma based on National Heart, Lung, and Blood Institute guidelines.

110 The National Heart, Lung, and Blood Institute has a strong interest i

111 tional Institutes of Health and the National Heart, Lung, and Blood Institute have developed new appr

112 s in 5 cohorts participating in the National Heart, Lung, and Blood Institute HIV-CVD Collaborative t

113 novo (type 1) R01 grants funded by National Heart, Lung, and Blood Institute in fiscal year 2009: th

114 Although the National Heart, Lung, and Blood Institute increased funding of ca

115 cent National Institutes of Health, National Heart, Lung, and Blood Institute initiative on integrati

116 is a National Institutes of Health/National Heart, Lung, and Blood Institute initiative to reclassif

117 Senior program staff at the National Heart, Lung, and Blood Institute invite the epidemiology

118 The National Heart, Lung, and Blood Institute of the National Institu

119 d Digestive and Kidney Diseases and National Heart, Lung, and Blood Institute of the National Institu

120 uestions of treatment and care, the National Heart, Lung, and Blood Institute of the National Institu

121 National Heart, Lung, and Blood Institute of the National Institu

122 The National Heart, Lung, and Blood Institute of the U.S.

123 The National Institutes of Health/National Heart, Lung, and Blood Institute Pediatric Heart Network

124 Data consisted of accessing National Heart, Lung, and Blood Institute public information, dat

125 We assessed study quality using the National Heart, Lung, and Blood Institute quality assessment tool

126 1492 investigator-initiated de novo National Heart, Lung, and Blood Institute R01 grant applications

127 In 2006, the National Heart, Lung, and Blood Institute released a funding oppo

128 As funders of research, we at the National Heart, Lung, and Blood Institute seek to support project

129 The National Heart, Lung, and Blood Institute Severe Asthma Research

130 p summary from a recently conducted National Heart, Lung, and Blood Institute strategic planning work

131 based on a workshop convened by the National Heart, Lung, and Blood Institute to explore predictive a

132 virtual workshop convened by the US National Heart, Lung, and Blood Institute to identify important r

133 nt virtual workshop convened by the National Heart, Lung, and Blood Institute to identify key researc

134 ipants of diverse ancestries in the National Heart, Lung, and Blood Institute Trans-omics for Precisi

135 lowed up to 2010 in the prospective National Heart, Lung, and Blood Institute Twin Study.

136 nal cohort studies sponsored by the National Heart, Lung, and Blood Institute were used to create a c

137 The overarching purpose of the National Heart, Lung, and Blood Institute workshop on "Malformed

138 An Executive Summary of a National Heart, Lung, and Blood Institute workshop on this topic

139 mericans and 471 Europeans from the National Heart, Lung, and Blood Institute's (NHLBI) Exome Sequenc

140 the double-blind, 3-way, crossover National Heart, Lung, and Blood Institute's Asthma Clinical Resea

141 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, wi

142 academic US medical centers in the National Heart, Lung, and Blood Institute's AsthmaNet network, wi

143 To that end, the National Heart, Lung, and Blood Institute's Center for Translatio

144 ancestry participants from CHARGE, National Heart, Lung, and Blood Institute's Exome Sequencing Proj

145 xomes of >5000 individuals from the National Heart, Lung, and Blood Institute's Exome Sequencing Proj

146 The National Heart, Lung, and Blood Institute's Growth and Health Stu

147 patient and clinician uptake of the National Heart, Lung, and Blood Institute's National Asthma Educa

148 The National Heart, Lung, and Blood Institute's Next Generation Genet

149 study was completed as part of the National Heart, Lung, and Blood Institute's Severe Asthma Researc

150 ure and relatedness, such as in the National Heart, Lung, and Blood Institute's Trans-Omics for Preci

151 All of Us Research Program and the National Heart, Lung, and Blood Institute's Trans-Omics for Preci

152 d access database obtained from the National Heart, Lung, and Blood Institute's Viral Activation Tran

153 e National Heart Institute (now the National Heart, Lung, and Blood Institute) in its very early days

154 n with interested parties (from the National Heart, Lung, and Blood Institute, American Heart Associa

155 Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, and the American Diabe

156 National Heart, Lung, and Blood Institute, and the COPD Foundatio

157 m the Food and Drug Administration, National Heart, Lung, and Blood Institute, Centers for Medicare a

158 ion, American Heart Association, US National Heart, Lung, and Blood Institute, Columbia University, H

159 US National Heart, Lung, and Blood Institute, National Center for Ad

160 National Heart, Lung, and Blood Institute, National Institute of

161 National Heart, Lung, and Blood Institute, National Institute of

162 National Heart, Lung, and Blood Institute, National Institutes of

163 The National Cancer Institute, the National Heart, Lung, and Blood Institute, the National Institute

164 The National Heart, Lung, and Blood Institute, through a request for

165 US National Heart, Lung, and Blood Institute, US National Center for

166 With support from the National Heart, Lung, and Blood Institute, we established the Con

167 tissue engineering programs of the National Heart, Lung, and Blood Institute, which support research

168 is hypothesis, we have launched the National Heart, Lung, and Blood Institute- and National Human Gen

169 The National Heart, Lung, and Blood Institute-funded Pediatric Cardia

170 Studies from the National Heart, Lung, and Blood Institute-funded Pediatric Cardio

171 hildren with FDCM or IDCM using the National Heart, Lung, and Blood Institute-funded Pediatric Cardio

172 ophic Cardiomyopathy Registry) is a National Heart, Lung, and Blood Institute-funded, prospective reg

173 icle highlights several examples of National Heart, Lung, and Blood Institute-initiated translational

174 in clinical trials conducted by the National Heart, Lung, and Blood Institute-sponsored Asthma Clinic

175 eiving maximal medical therapy at 5 National Heart, Lung, and Blood Institute-sponsored Cardiovascula

176 -release and internal datasets from National Heart, Lung, and Blood Institute-sponsored cohorts, we e

177 and between races in 3 multicenter, National Heart, Lung, and Blood Institute-sponsored cohorts.

178 is a large, predominantly biracial, National Heart, Lung, and Blood Institute-sponsored epidemiologic

179 exercise capacity, conducted in the National Heart, Lung, and Blood Institute-sponsored Heart Failure

180 Genomic DNAs from 223 subjects of 2 National Heart, Lung, and Blood Institute-sponsored randomized cl

181 We performed the first National Heart, Lung, and Blood Institute-sponsored trial of post

182 and with no obstructive CAD in the National Heart, Lung, and Blood Institute-sponsored WISE (Women's

183 The large-scale National Heart, Lung, and Blood Institute-sponsored, randomized H

184 jected With ALDH Bright Cells) is a National Heart, Lung, and Blood Institute-sponsored, randomized,

185 ity measures included the number of National Heart, Lung, and Blood Institute-supported publications

186 National Institutes of Health, National Heart, Lung, and Blood Institute.

187 This trial was funded by the National Heart, Lung, and Blood Institute.

188 ce: National Institute on Aging and National Heart, Lung, and Blood Institute.

189 review originally initiated by the National Heart, Lung, and Blood Institute.

190 National Heart, Lung, and Blood Institute.

191 alth and Human Development, and the National Heart, Lung, and Blood Institute.

192 The National Heart, Lung, and Blood Institute.

193 l treatment trials performed by the National Heart, Lung, and Blood Institute.

194 nd ALVEOLI trial), sponsored by the National Heart, Lung, and Blood Institute.

195 iovascular outcomes research by the National Heart, Lung, and Blood Institute.

196 or Medicare & Medicaid Services and National Heart, Lung, and Blood Institute.

197 y Research Network sponsored by the National Heart, Lung, and Blood Institute.

198 PRIMARY FUNDING SOURCE: National Heart, Lung, and Blood Institute.

199 the critical care community and the National Heart, Lung, and Blood Institute.

200 We conducted a National Heart, Lung, and Blood Institute/National Cancer Institu

201 US National Heart, Lung, and Blood Institute/National Institutes of

202 Texas Southwestern Medical Center; National Heart, Lung, and Blood Institute; and American Heart Ass

203 e of Environmental Health Sciences; National Heart, Lung, and Blood Institute; and Merck Childhood As

204 e NIH Office of Disease Prevention; National Heart, Lung, and Blood Institute; and National Institute

205 arities; National Cancer Institute; National Heart, Lung, and Blood Institute; and National Institute

206 or Healthcare Research and Quality; National Heart, Lung, and Blood Institute; and Society of Critica

207 National Institutes of Health and National Heart, Lung, and Blood Institute; National Institute on

208 The WHI program is funded by the National Heart, Lung, and Blood Institute; National Institutes of

209 National Institutes of Health; National Heart, Lung, and Blood Institute; Pulmonary Fibrosis Fou

210 US National Heart, Lung, and Blood Institute; the Alpha-1 Foundation

211 US National Heart, Lung, and Blood Institute; Wyeth.

212 convened a Working Group to address emerging heart, lung, and blood research priorities related to HI

213 gulator across several organs, including the heart, lung, and brain, suggesting that it is a fundamen

214 ssues including kidney, pancreas, intestine, heart, lung, and brain.

215 al contractile and relaxation motions of the heart, lung, and diaphragm, demonstrated in several diff

216 2, 6.7%), heart (N = 2, 6.7%), and combined heart, lung, and kidney (N = 1, 3.3%).

217 udies and the potential relevance of this to heart, lung, and kidney allograft dysfunction.

218 nterstitial and perivascular fibrosis in the heart, lung, and kidney as a result of enhanced myofibro

219 robacteriaceae (54%) as urinary pathogens in heart, lung, and kidney transplant recipients, and as di

220 rdependent feedback mechanisms involving the heart, lung, and kidney.

221 All surviving heart, lung, and liver transplant patients from Auckland

222 ipheral inflammatory responses in the blood, heart, lung, and spleen remained unchanged.

223 in cases of kidney, liver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfu

224 To the extent that diseases of the heart, lungs, and blood are associated with impaired tis

225 erapeutics for I-R injury in kidneys, liver, heart, lungs, and brain.

226 rphogenesis of asymmetric organs such as the heart, lungs, and stomach.

227 idney-pancreas, 7.3% small bowel/liver, 5.7% heart/lung, and 3.3% multivisceral.

228 Rat heart-lung blocks were placed on EVLP for 4 hours with o

229 by the American Heart Association / National Heart Lung Blood Institute criteria (HR, 0.63; 95% CI, 0

230 pproximately 50 000 SNPs from 2000 candidate heart, lung, blood and sleep genes.

231 ilding on the track record of success of the heart, lung, blood, and sleep cohorts to leverage new da

232 d the distribution of these grants among the heart, lung, blood, and sleep disease areas as well as t

233 te future directions for the epidemiology of heart, lung, blood, and sleep diseases.

234 s in population sciences and epidemiology of heart, lung, blood, and sleep diseases; 2) developing me

235 r new understanding of nature's solutions to heart, lung, blood, and sleep disorders through future r

236 erstanding and control of conditions such as heart, lung, blood, and sleep disorders.

237 strong foundation for the transformation of heart, lung, blood, and sleep epidemiology.

238 ies in data science to open new frontiers in heart, lung, blood, and sleep research is one of the maj

239 motion), and training the next generation of heart, lung, blood, and sleep researchers.

240 Disparities in health outcomes for heart, lung, blood, and sleep-related health conditions

241 mentation science research in the context of heart, lung, blood, and sleep-related health conditions.

242 r early stage investigator career success in heart, lung, blood, and sleep-related research.

243 ould inform prevention strategies for common heart-lung conditions.

244 raniofacial skeleton, ear, branchial arches, heart, lungs, diaphragm, gut, kidneys, and gonads.

245 Region Vastra Gotaland, Sweden), the Swedish Heart-Lung Foundation, Diabetes Wellness, Novo Nordisk F

246 Swedish Heart-Lung Foundation, Novo Nordisk Foundation, and Swed

247 Swedish Heart-Lung Foundation, Swedish Research Council, Austral

248 Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Resea

249 ource: The Swedish Research Council, Swedish Heart-Lung Foundation, Swedish Society for Medical Resea

250 on of Local Authorities and Regions, Swedish Heart-Lung Foundation.

251 Research Council (Vetenskapsradet), Swedish Heart-Lung Foundation.

252 ch Council of Norway, AFA Insurance, Swedish Heart Lung Fund, Foundation of Marianne and Marcus Walle

253 rvate the majority of visceral organs (e.g., heart, lungs, GI tract, etc) and their activation is cri

254 cluding engineered models of diseases of the heart, lung, intestine, liver, kidney, cartilage, skin a

255 rgan status (for a liver in combination with heart, lung, intestine, or pancreas) and then on a natio

256 ially accumulated in more organs such as the heart, lung, kidney, etc.

257 escribed adult human subjects who received a heart, lung, kidney, or liver allograft.

258 that Pikfyve is critical in neural tissues, heart, lung, kidney, thymus, and spleen.

259 curement of significantly greater numbers of hearts, lungs, kidneys, pancreases, and intestines, but

260 e lifesaving solid organ transplantation for heart, lung, liver, and kidney recipients.

261 At the end of treatment, heart, lung, liver, and kidney tissue was harvested to d

262 atest concentrations of rickettsial DNA from heart, lung, liver, and spleen samples when examined by

263 pediatric solid-organ transplant recipients (heart, lung, liver, kidney, multiorgan) at Hospital for

264 pediatric solid-organ transplant recipients (heart, lung, liver, kidney, multiorgan) at The Hospital

265 ion management of this novel infection among heart, lung, liver, pancreas, and kidney transplant reci

266 settings and organ transplant types (kidney, heart, lung, liver, pancreas, intestinal, and islet cell

267 ere higher than DAT/Cremophor EL micelles in heart, lung, liver, spleen, and kidney.

268 calculated for major organs including brain, heart, lungs, liver, kidneys, spleen, muscle, bone, and

269 t study of 8026 patients receiving a kidney, heart, lung, or liver transplant in Norway from 1968 thr

270 selective I/R to organs such as the kidney, heart, lung, or liver.

271 During a 10-year period, selected kidney, heart, lung, pancreas, liver, and composite tissue recip

272 icitly coded sepsis, and SOT (kidney, liver, heart, lung, pancreas, or intestine transplants).

273 rs; M-to-F ratio, 17:13; single-to-double-to-heart lung ratio, 5:24:1).

274 tissue repair in the liver, nervous system, heart, lung, skeletal muscle, and intestine and illustra

275 annel organ chips (intestine, liver, kidney, heart, lung, skin, blood-brain barrier and brain) for 3

276 as performed to estimate rickettsial load in heart, lung, spleen, and liver tissues of infected mice

277 The accumulation of 800CW-BSA was low in the heart, lung, spleen, kidneys, and liver, but high in the

278 s of a massive iron deposition in the liver, heart, lungs, spleen, bone marrow, thyroid and adrenal g

279 s of COVID-19 disease, with an emphasis on a Heart-Lung team approach in patient management.

280 define the identities of fibroblasts in the heart, lungs, trachea, and bladder.

281 and absence of The International Society for Heart & Lung Tranplantation primary-graft dysfunction gr

282 d according to the International Society for Heart Lung Transplant system for cellular rejection with

283 percutaneous coronary intervention; or heart/heart-lung transplant).

284 ving PGD using the International Society for Heart & Lung Transplantation (ISHLT)-defined criteria.

285 Heart lung transplantation is a viable treatment option

286 ventilation (MV) can be used as a bridge to heart-lung transplantation (HLT).

287 Heart-lung transplantation (HLTx) is an effective treatm

288 01), hospitalization for PAH, and/or lung or heart-lung transplantation (OR: 0.442; 95% CI: 0.309 to

289 Both heart-lung transplantation and double-lung transplantati

290 On multivariable analysis, heart-lung transplantation and double-lung transplantati

291 nevertheless, both lung transplantation and heart-lung transplantation candidates in this era enjoye

292 without ECMO (BLTx ventilation) or combined heart-lung transplantation for severe PH.

293 charts of patients undergoing either lung or heart-lung transplantation in a tertiary transplantation

294 linical outcomes for patients after combined heart-lung transplantation in the current era.

295 Patients with CF who underwent lung or heart-lung transplantation in the United States or Unite

296 A rodent heterotopic working heart-lung transplantation model was used for studying a

297 Heart-lung transplantation or bilateral lung transplanta

298 Lung transplantation and heart-lung transplantation represent surgical options fo

299 ungs (n=7) from patients with PAH undergoing heart/lung transplantation and compared with tissue obta

300 s using RV tissue of PAH patients undergoing heart/lung transplantation and nonfailing donors.